1. A method of vaccinating against Zika virus infection in a human subject in need thereof, the method comprising administering to the human subject a vaccine or immunogenic composition comprising an antigen from a Zika virus, wherein the vaccine or immunogenic composition is administered as a multi dose administration comprising a first (prime) and a second (boost) administration and wherein administration of the vaccine or immunogenic composition induces 14 and/or 28 days after the boost administration a seroconversion rate of at least 80%, at least 90%, at least 95%, or 100% in a human subject population of at least 20 flavivirus naïve human subjects or at least 20 Zika virus seronegative human subjects.
|